Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

alone) in patients with chronic hepatitis C virus genotype 1 infections who were characterized as non-responders to prior therapy with optimized pegylated alpha interferon plus ribavirin.

Data from the Phase II non-responder study were presented on April 15, 2007 at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) held in Barcelona, Spain and on May 21, 2007 at Digestive Disease Week (DDW) 2007 held in Washington, DC.

On June 26, 2007, Schering-Plough advised us that they would not be entering into a second period of exclusivity to negotiate the terms of a license agreement for celgosivir at that time. MIGENIX is now in various stages of discussions with other interested parties for the partnering of celgosivir.

A Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection who have not received prior treatment for their infection is ongoing. The focus of this study is on viral kinetics, pharmacokinetics, safety and tolerability of celgosivir in combination with peginterferon alfa-2b with ribavirin. As reported previously, enrollment in the study has been slower than anticipated. Interim 4-week data from the study are expected in approximately 10 patients in October 2007, with guidance for 12-week data to be provided in conjunction with the 4-week data.

All MIGENIX-related clinical trials of celgosivir to date have been conducted in Canada. An Investigational New Drug (IND) application is planned to be submitted to the US FDA in the first quarter of 2008 for the future development of celgosivir.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Cutanea Life Sciences, Inc., our development and commercialization partner for CLS001, is conducting a Phase II rosacea clinical trial in the United States. The Phase II trial is a randomized, vehicle-controlled, double-blind, multi-center study designed to evaluate the safety and
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Calif. , May 17, 2013 /PRNewswire-iReach/ -- ... has been reached with Switzerland ... of anti-infective human monoclonal antibody (mAb) products, and ... human mAb products for treatment of infections by ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... May 17, 2013 Rust removal is one ... non-metal home items could be damaged. To help rust contractors ... of its no-scrubbing rust remover it called Rusterizer. ... available with 10% discount. , My Cleaning Products explained that ... them or by staining them. The first one, it ...
(Date:5/16/2013)... Oven Industries, Inc. has been an ... temperature sensors since 1964. Expertly designed, the proportional-integral-derivative ... system applications. As one of the most ... control loop feedback system, which helps minimize errors. With ... a systematic process, using a control element, like a ...
(Date:5/16/2013)...  HealthSparq, a trusted provider of healthcare transparency ... health plans, will debut a new benchmark study ... 2013 conference on June 13.  The presentation will ... insurance companies across the country are thinking about ... for increased healthcare transparency. This ...
Breaking Biology Technology:Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2New PID Temperature Controllers Announced by Oven Industries Inc. 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3
... the titans of e-commerce have been identified, search engines ... same time, serious questions are emerging related to the ... the search engines collide? and, How soon and why ... principal devices for business access, then todays search results, ...
... this barrel spring, are old enough not to be patented ... the past decade, the economy has been experiencing an accelerated ... A patent for a novel medical device, an internet-based business ... drug design in the pharmaceutical industry can form the basis ...
... Chippewa Valley, Wis. — Silicon Graphics Inc. ... it was the company's Chippewa Falls, Wisconsin, plant that pulled ... million project for NASA last week. , ,The ... year, runs on SGIs Altix 3700 systems and ...
Cached Biology Technology:When search engines collide 2When search engines collide 3When search engines collide 4Patent essentials for business owners: from patent to profit 2Patent essentials for business owners: from patent to profit 3Patent essentials for business owners: from patent to profit 4Patent essentials for business owners: from patent to profit 5SGIs Wisconsin branch builds fastest supercomputer yet in four months 2
(Date:5/16/2013)... conservationist working in Cameroon and the manager of San ... awarded the prestigious Whitley award. The Whitley award ... Green Oscars" because it celebrates the extraordinary achievements of ... countries. Abwe was selected for the award due ... Ebo Forest and its wildlife inhabitants., HRH The Princess ...
(Date:5/16/2013)... 16, 2013 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... practises such as photographs, passwords and PIN ... technologies in last few years. Security threats ...
(Date:5/15/2013)... studies touting its benefit in moderating gout risk, new ... does not reduce uric acid (urate) levels to a ... C supplementation, alone or in combination with allopurinol, appears ... levels in gout patients according to the results published ... Arthritis & Rheumatism . , Gout is an ...
Breaking Biology News(10 mins):Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7Vitamin C does not lower uric acid levels in gout patients 2
... clues on risk factors and biological causes of a ... to a new study from an international genetics team ... at the University of Pennsylvania. In the largest genetics ... risk for PSP were identified and two additional genetic ...
... Heavy and prolonged snowfall can bring about unexpected conditions ... in the Arctic, according to experts. A new international ... helps plants to grow bigger, heavy and prolonged snow can, ... of killer fungal strains. The research results, published in ...
... have long known that cramming is not an effective ... at the RIKEN Brain Science Institute in Japan, studying ... neurological mechanism explaining why this is so. Published in ... that protein synthesis in the cerebellum plays a key ...
Cached Biology News:New genes for risk and progression of rare brain disease identified 2New genes for risk and progression of rare brain disease identified 3Arctic snow harbors deadly assassin 2A better way to remember 2
... All serum is extensively ... release criteria. All horses ... Diet and worming are controlled ... to lot consistency. Pricing: ...
Mouse Aminopeptidase P2/XPNPEP2 Biotinylated Aff Pur PAb Keywords: AminopeptidaseP2, Metalloproteinase, Metalloprotease, X-Prolyl Aminopeptidase 2, X-Pro Aminopeptidase 2, Membrane-bound Prote...
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
Biology Products: